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Abstract
Background: Galectin-7 (Gal-7) is negatively regulated in cervical cancer, and appears to be a link between the
apoptotic response triggered by cancer and the anti-tumoral activity of the immune system. Our understanding of
how cervical cancer cells and their molecular networks adapt in response to the expression of Gal-7 remains limited.
Methods: Meta-analysis of Gal-7 expression was conducted in three cervical cancer cohort studies and TCGA.
In silico prediction and bisulfite sequencing were performed to inquire epigenetic alterations. To study the effect
of Gal-7 on cervical cancer, we ectopically re-expressed it in the HeLa and SiHa cervical cancer cell lines, and analyzed
their transcriptome and SILAC-based proteome. We also examined the tumor and microenvironment host cell
transcriptomes after xenotransplantation into immunocompromised mice. Differences between samples were assessed
with the Kruskall-Wallis, Dunn’s Multiple Comparison and T tests. Kaplan–Meier and log-rank tests were used to
determine overall survival.
Results: Gal-7 was constantly downregulated in our meta-analysis (p < 0.0001). Tumors with combined high Gal-7
and low galectin-1 expression (p = 0.0001) presented significantly better prognoses (p = 0.005). In silico and bisulfite
sequencing assays showed de novo methylation in the Gal-7 promoter and first intron. Cells re-expressing Gal-7
showed a high apoptosis ratio (p < 0.05) and their xenografts displayed strong growth retardation (p < 0.001). Multiple
gene modules and transcriptional regulators were modulated in response to Gal-7 reconstitution, both in cervical
cancer cells and their microenvironments (FDR < 0.05 %). Most of these genes and modules were associated with
tissue morphogenesis, metabolism, transport, chemokine activity, and immune response. These functional modules
could exert the same effects in vitro and in vivo, even despite different compositions between HeLa and SiHa samples.
Conclusions: Gal-7 re-expression affects the regulation of molecular networks in cervical cancer that are involved in
diverse cancer hallmarks, such as metabolism, growth control, invasion and evasion of apoptosis. The effect of Gal-7
extends to the microenvironment, where networks involved in its configuration and in immune surveillance are
particularly affected.
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Background
Galectins are a family of carbohydrate-binding proteins
involved in immune response, angiogenesis and cancer
development [1]. Different members of the galectin fam-
ily, such as galectin-1 (Gal-1) and galectin-7 (Gal-7),
have been found to influence the pathogenesis of cer-
vical cancer (CaCx). The expression of Gal-1 is function-
ally linked to histopathological grading in cervical cancer
patients, namely by affecting the rate of proliferation,
lymph node metastasis and tumor invasion [2]. Gal-1 is
also the receptor for Trichomonas vaginalis [3], a
sexually transmitted protozoan parasite and risk factor
for cervical cancer [4]. In contrast, Gal-7 is preferentially
expressed in stratified squamous epithelia from skin,
genital and upper digestive track [5]. Gal-7 is a p53-
inducible gene, which is upregulated in response to UVB
radiation in normal human keratinocytes [6].
As an endogenous lectin, a fraction of Gal-7 is consti-
tutively localized at the mitochondria. It has been found
to interact with the anti-apoptotic protein Bcl-2, sug-
gesting its regulatory role in apoptotic processes [7].
Importantly, increased Gal-7 expression has been shown
as a positive predictive biomarker for clinical responses
after adjuvant radiation therapy in cervical cancer
patients [8]. While a plethora of distinct properties of
Gal-7 are known, an integrative analysis of the molecular
mechanisms with which Gal-7 expression shapes the
tumorigenic process has not yet been performed.
In the present study, we performed an integrative ana-
lysis of the impact of Gal-7 reconstitution in cervical
cancer cells and their microenvironment at the systems
level in silico, in vitro, and in a mouse model. For that
purpose, we conducted a meta-analysis of a whole
spectrum of clinical data in which cervical cancer pa-
tients showed a significant longer life span when tumors
had simultaneous high Gal-7 and low Gal-1 expression.
To validate these observations in the biological system,
we ectopically expressed Gal-7 in CaCx cell lines and
evaluated them through transcriptomics, SILAC-based
proteomics, gene methylation profiling, and network
analysis. We identified numerous circuits implicated in
cancer hallmarks that were affected by Gal-7 re-expression
(Fig. 1a). These results suggest a bi-directional regulation
between the tumor and its microenvironment where Gal-7
could be a critical mediator.
Methods
Galectin expression profiles in independent cohorts of
cervical cancer
To analyze the expression profiles of the galectin genes
in cervical epithelium, we used the data from the differ-
ential expression profiles established by Scotto et al. [9]
(Gene Expression Omnibus NCBI, GEO accession num-
ber GSE9750). The cohort consists of three groups of 24
normal cervical epithelium samples, a panel of nine
CaCx cell lines and 28 squamous cervical cancer sam-
ples (SCC). Clinical samples represent the different can-
cer stages as suggested by the International Federation
of Gynecology and Obstetrics (FIGO) [10]. The diffe-
rential expression analyses were held using the reported
signal intensity information for each galectin gene.
Comparisons among groups were performed using a
Kruskall-Wallis test followed by a post-hoc Dunn’s mul-
tiple comparison test. To test the Gal-7 profile through
the CaCx progression, we used the cohort analysis estab-
lished by Zhai et al. [11], (GEO accession number
GDS3292) composed of 10 normal cervix, 7 high-grade
squamous intraepithelial lesion (HSIL) samples and 21
SCCs. The Zhai cohort was used to study the modula-
tion of Gal-7 along the process of transformation to-
wards malignancy.
Hierarchical clustering and survival analysis
To study the expression profiles of Gal-7 and Gal-1 genes,
the data compiled in a Provisional cohort (November 2014)
for Cervical Squamous Cell Carcinoma and Endocervical
Adenocarcinoma from The Cancer Genome Atlas (CESC-
TCGA) [12] were used. This consisted of 185 RNA-Seq
samples from patients in different tumor stage and
grading. RNA-Seq Expectation-Maximization (RSEM)
[13] data normalized by TCGA were used directly. The
comparisons among groups were performed using a
Kruskall-Wallis test followed by a post-hoc Dunn’s mul-
tiple comparison tests.
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Fig. 1 (See legend on next page.)
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Unsupervised Hierarchical clustering was performed
on a centered Pearson correlation coefficient algorithm
and a complete linkage method to compare the expres-
sion patterns of the Gal-7 and Gal-1 genes across the
CESC-TCGA data set. Overall survival (OS) was defined
from the day of the sample intake to the patient’s death.
Data of the patients who had survived until the end of
the observation period were censored at their last
follow-up visit. The OS curve was plotted using the clus-
ters obtained from the hierarchical clustering analysis,
using the Kaplan-Meier method. A log-rank test was
used to compare the survival curves. All the statistical
analysis and graphics were performed using R environ-
ment, version 3.0.1 (2013-05-16) “Good Sport”.
CESC-TCGA data methylation analysis
The relationship between Gal-7 methylation and mRNA
expression was analyzed using the CESC-TCGA Methy-
lation data versus mRNA expression. To confirm the
correlations, the Spearman’s rank correlation coefficient
was used, with a two-tailed P-value and an alpha = 0.05.
Analysis of methylation
Bisulfite-PCR-pyrosequencing focused on 13 CpG sites
between nt −294 and nt +132 of the Gal-7 gene (the
target region encompasses the promoter, the first exon
and the first intron of the gene; the Eukaryotic Promoter
Database ID: LGALS7 (chr19:39,262,157–39,266,157)
was employed. PCR primers were designed on the in
silico-converted target sequence, with the correspondent
sequencing primers, to generate two products (Additional
file 1: Table S2). Total DNA (500 ng) extracted from cells
underwent bisulfite conversion by using the EZ DNA
MethylationTM Kit (Zymo reasearch), following manufac-
turer’s instruction. Two PCR reactions were performed in
a final volume of 50 μl with 200 mM dNTPs mix, 500 nM
each primer, 2.5 mM MgCl2, 0.62 U Hot Start GoTaq®
DNA polymerase (Promega) and 5 μl of bisulfite-
converted DNA, under the following conditions: 95 °C for
2 min, 50 cycles of 95 °C for 30 s, 56 °C for 30 s, 72 °C for
30 s and final extension at 72 °C for 10 min. For the se-
quencing reactions of the PCR products, the PyroMark™
Q24 System (Qiagen) was used following manufacturer’s
instructions (400 nM of one sequencing primer/reaction).
The final pyrograms were analyzed using the allele quanti-
fication (AQ) mode in the PyroMark™ Q24 Software, to
determine the proportion of C/T (forward sequencing)
and, hence, the methylation frequency of the target
CpG sites.
Cell culture, azacytidine treatment
HPV16 immortalized human keratinocytes, HeLa, SiHa
and CaSki Gal-7 positive and control cells as well as 293 T
cells were maintained under standard conditions in
Dulbecco’s modified Eagle medium supplemented with
10 % Fetal Calf Serum and 1 % penicillin/streptomycin
(P/S). Azacytidine (5′-Aza; Cayman) was dissolved in
DMSO (Merck). Treatment was done for four days
using 1 (HeLa) to 10 (SiHa and CaSki) μmol/L.
Gal-7 cloning and retrovirus construction
The Human Gal-7 gene cloned in the pEF1 vector
[14] was amplified by PCR using primers containing
the restriction sites XhoI and BamHI: Gal-7-XhoI-F:
5′-GAGCTCGAGCCGCCATGTCCAACGTCCCCCAC
AA-3′ and Gal-7-BamHI-R: 5′-GCGCGGATCCTCAG
AAGATCCTCACG-3′ under the following parame-
ters: denaturation at 98 °C for 3 min, followed by
30 cycles at 94 °C 30 s, 58 °C 45 s, 72 °C 1 min and
a final extension at 72 °C for 10 min. Subsequently,
2 μg of Gal-7 insert DNA was digested with XhoI
and BamHI enzymes (Fermentas, Sankt Leon-Rot) for
1 h at 37 °C and purified using the QIAquick® PCR
Purification Kit (Qiagen, Hilden). Afterwards, the
digested product was ligated into pLXSN viral vector
previously digested with XhoI and BamHI and de-
phosphorylated. Subcloning was further validated by
sequencing of the resulting pLXSN-Gal-7 construct
(GATC Biotech, Germany). For production of viral
particles, 293 T cells were transfected with the con-
struct pLXSN-Gal7 together with the corresponding
retroviral packaging vectors pVSV.G [15] and pSVΨ
[16]. Viral particles containing empty pLXSN vector
were also produced as control. 293 T cell supernatant
was harvested and filtered through a 0.45 μm filter
(Minisart Plus, Sigma-Aldrich). Filtered supernatant
was mixed with 5 μg/ml of the cationic polymer
Polybrene® and used for infection of CaSki, HeLa and
SiHa cells. After infection, the cells were subjected to
antibiotic selection with G418 for two weeks (Life
Technologies). Gal-7 expression was finally analyzed
by Western blot.
(See figure on previous page.)
Fig. 1 Study design and galectin expression in cervical cancer. a Pipeline of the complete experimental approach. b Gene expression profiles of
galectin family members in clinical samples (normal cervix and squamous cell carcinoma, SCC) and CaCx cell lines obtained from the Scotto cohort.
c Gal-7 transcription in normal cervical tissue, high grade squamous intraepithelial lesions (HSIL) and squamous cell carcinomas (SCC) from the Zhai
cohort. d qPCR and Western blot analysis of Gal-7 in primary keratinocytes (PK), HPV 16 E6, E7 and E6/E7 immortalized human keratinocytes, and CaCx
cells (CaSki, SiHa, HeLa). e Analysis of Gal-7 expression in clinical samples (derived from HPV16 positive SCCs) and normal tissue. (BKruskall-Wallis Test,
P < 0.0001, Dunn’s Multiple Comparison Test P < 0.05; ET Test, P < 0.05, *** means highly significant, ** moderately significant)
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Protein extraction and Western blotting
Gal-7+ cervical tumor cell lines and the respective con-
trol cells were collected, washed in 1 × PBS and resus-
pended in RIPA buffer (20 mM Tris pH 7.5; 150 mM
NaCl; 1 mM Na2EDTA; 1 mM EGTA; 1 % NP-40; 1 %
sodium deoxycholate) containing 1× complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim). Pro-
tein extraction was performed by incubating for 30 min
on ice and subsequently centrifuging for 30 min at 4 °C
and 13,000 rpm. Supernatants were quantified using the
Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-
Rad, Munich). 80 μg protein/lane was used for Western
blotting. After transfer, the PDVF filters were incubated
with the following antibodies: anti-human Galectin-7,
epr4287 (Genetex, USA), anti-Tubulin (G8), sc-55,529
(Santa Cruz Biotechnology, USA). Blots were developed
using the Western lightning plus-ECL system (Perkin
Elmer, Rodgau).
Colony formation assay and mitochondrial membrane
potential measurements
The colony formation assay was essentially performed as
described by Rotem et al. [17]. HeLa cells were cultured
at 500, CaSki and SiHa at 1×103 cells in 6-well plates.
Cells were cultured for 7 days or until overlapping col-
onies started to appear. Cells were then briefly washed
with DPBS and fixed for 30 min with a 10 % glutaralde-
hyde solution. Colonies were stained with 6 % crystal
violet for 30 min. Each well in the plate was photo-
graphed with a Stereomicroscope (Olympus, Hamburg)
and the colonies were automatically counted using the
image processor software ImageJ.
To measure mitochondrial membrane potential,
15,000 cells from each cell line were plated in 100 μl
normal DMEM in 96-well μClear black plates. The next
day, the cells were treated with different concentrations
of HA14-1 (10 μM, 25 μM and 40 μM) for 24 h. Afterwards,
100 μL/well of 30nM JC-1 Solution (Life Technologies,
Darmstadt) were added and the cells were incubated for
30 min at 37 °C in the dark. After washing the plates twice
with 1× Dilution Buffer solution (PBS + 2 % FCS) fluores-
cence measurement was performed by reading the plate in
a Synergy 2 Multi-Mode microplate reader with the
following settings: excitation: 475 nm, emission at 530
(monomers emission) and 590 nm (aggregate emission). A
decrease in the ratio between the fluorescence of mono-
mers and aggregates indicates mitochondrial depolar-
ization and cell death.
Animal tumor model
7–8 week-old female nude Balb/c mice (Janvier Labs, St
Berthevin, France) were maintained under pathogen-free
conditions. 5×105 (HeLa and HeLa Gal-7) or 5×106
(SiHa and SiHa Gal-7) cells were suspended in 100 μl or
200 μl ice-cold PBS and subcutaneously implanted into
the flanks of mice (5 mice/group). Tumor sizes were
measured with an electronic digital caliper (Farnell,
Germany) three times a week and the tumor volume
was calculated according to the formula: V = 1/2 ×
length × width2 (mm3). Animals were killed according to
the animal welfare act when a tumor volume reached a
volume of 1500 mm3. The animals at the German
Cancer Research Center were maintained in compliance
with German and European statutes and all animal ex-
periments were undertaken with the approval of the re-
sponsible Animal Ethics Committee.
RNA extraction, reverse transcription and quantitative
PCR analysis
RNA was extracted from cells using the RNeasy Mini
Kit (Qiagen) according to the manufacturer’s instruc-
tions. One μg of RNA was reverse transcribed using
RevertAid Reverse Transcriptase (Thermo Scientific,
USA) and dT22primers according to the manufacturer’s
protocol. The resulting cDNA was used for quantitative
PCR analyses using the CFX96 Touch™ Real-Time PCR
Detection System (BioRad, USA), the iTaq Universal
SYBR Green (BioRad, USA) and the primers described
in Additional file 1: Table S3.
Gene expression profiling analysis
RNA was extracted from tissue culture cells using the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. A total of 500 ng of RNA from every sample
was labeled and hybridized in the HumanHT-12v4 expres-
sion BeadChip (Illumina) following standard procedures
of the Genomic Core facility at the DKFZ. For the tumors,
fresh-frozen xenotransplants isolated from nude mice
were homogenized in a Precellys® 24 tissue homogenizer
(Bertin Tech. USA). Subsequently, RNA from tumors was
isolated using standard TRIZOL procedure (Invitrogen)
and Direct-zol RNA (Zymo Research) following the manu-
facturer’s instructions. Samples within the groups were
pooled. A total of 500 ng of RNA from every pooled group
was labeled and hybridized in the HumanHT-12v4 expres-
sion BeadChip (for human genes) or the mouseWG-6v2
expression BeadChip (for mouse genes) following stand-
ard procedures of the Genomic Core facility at the DKFZ.
Bioinformatic data analysis was performed using Chipster
[18] software version 3.1. mRNAs with a fold change of at
least 2 between Gal-7 negative and Gal-7 positive cells or
tumors were considered significant and were used for fur-
ther analysis.
Cell lysis and protein digestion for mass spectrometry
analysis
Cell pellets were resuspended in 1 % (w/v) sodium deox-
ycholate (SDC) and 50 mM ammonium bicarbonate,
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boiled at 99 °C for 5 min and cooled to 4 °C. The lysates
were then treated with benzonase (Sigma-Aldrich,
Germany) in a final concentration of 150 U/mL for
60 min on ice. Insoluble material was removed by centri-
fugation at 14,000 G, 15 min, 4 °C. Protein concentra-
tion was determined by bicinchoninic acid protein assay
kit (Sigma-Aldrich, Germany). Corresponding light and
heavy lysates were mixed in 1:1 protein ratio. Lysates
were then reduced with 10 mM dithiothreitol at 37 °C
for 60 min, alkylated with 20 mM iodoacetamide at RT
for 30 min in the dark and the unreacted iodoacetamide
was quenched with further 10 mM dithiothreitol at RT
for 15 min. The samples were diluted with 50 mM am-
monium bicarbonate to decrease the concentration of
SDC to 0.5 % and digested with sequencing grade tryp-
sin (Promega, USA) overnight at 37 C. SDC was re-
moved by the modified phase transfer protocol [19].
Briefly, ethyl-acetate was added and the digested product
was acidified by trifluoroacetic acid (TFA) to a final con-
centration of ca. 2 % (v/v). The mixtures were vortexed
vigorously for 1 min, centrifuged at 14,000 G for 5 min
and the upper organic layer was removed. The extrac-
tion was repeated with fresh portion of ethyl-acetate.
The aqueous phases were desalted on Empore™ extrac-
tion cartridges (Sigma-Aldrich, Germany) and dried in
vacuum.
SILAC labeling
HeLa and SiHa cells as well as their Gal-7 reconstituted
counterparts were SILAC labeled by cultivating the cells
for 5 passages in DMEM media (without glutamine, argin-
ine and lysine; Silantes 282,986,444) containing 10 % (v/v)
dialyzed FBS. Isotopically labeled L-lysine [13C6
15N2 -
labeled] 0.798 mM and L-arginine [13C6
15N4 - labeled]
0.398 mM (Silantes, Germany) were added to the DMEM
media (Fig. 4b). Unlabeled L-proline was added to a
final concentration of 2.61 mM (300 mg/L) to prevent
arginine-proline conversion [20].
Peptide separation and mass spectrometry analysis
Peptides were separated by two-dimensional liquid chro-
matography (LC). In the first dimension, reversed phase
LC under high-pH mobile phase conditions was per-
formed using Alliance 2695 LC system (Waters, UK).
The mobile phases were (A) water, (B) acetonitrile
(ACN) and (C) 200 mM ammonium formate pH 10.
Dried peptide mixtures were dissolved in 25 % C and
4 % ACN, and an aliquot of 200 μg was loaded on trap
column (Gemini C18, 2 × 4 mm) and column (Gemini
C18, 3 μm, 110 Å, 2 × 150 mm; Phenomenex, USA).
Peptide separation was performed by linear gradient
from 5 to 55 % of B in 62 min with constant 10 % of C.
Flow rate was 0.16 mL/min, the column was kept at 40 °C
and the separation was monitored at 215 nm. Fractions
were collected manually in 2-min intervals over the sam-
ple elution window from 10th to 52nd min, acidified with
TFA and dried in vacuum. The last 2 fractions were
combined with the first 2 fractions in sequential order.
Second dimension of the separation was performed on an
Ultimate 3000 RSLCnano system (Dionex, USA) coupled
on-line through Nanospray Flex ion source with Q-
Exactive mass spectrometer (Thermo Scientific, Germany).
Fractions were dissolved in 2 % ACN/0.05 % TFA and
loaded on capillary trap column (C18 PepMap100, 3 μm,
100 Å, 0.075 × 20 mm; Dionex) by 5 μL/min of 2 % ACN/
0.05 % TFA for 5 min. Then they were separated on capil-
lary column (C18 PepMap RSLC, 2 μm, 100 Å, 0.075 ×
150 mm; Dionex) by step linear gradient of mobile phase B
(80 % ACN/0.1 % FA) over mobile phase A (0.1 % FA)
from 4 to 34 % B in 48 min and from 34 to 55 % B in
10 min at flow rate of 300 nL/min. The column was kept
at 40 °C and the eluent was monitored at 215 nm. Spraying
voltage was 1.75 kV and heated capillary temperature was
275 °C. The mass spectrometer operated in the positive ion
mode performing survey MS (at 350–1650 m/z) and data-
dependent MS/MS scans on 10 most intense precursors
with dynamic exclusion window of 30 s. MS scans were ac-
quired with the resolution of 70,000 from 106 accumulated
charges; maximum fill time was 100 ms. The intensity
threshold for triggering MS/MS was set at 5×104 for ions
with z ≥ 2 and the isolation window was 1.6 Da. Normal-
ized collision energy for HCD fragmentation was 27 units.
MS/MS spectra were acquired with the resolution of
17,500 from 105 accumulated charges; maximum fill time
was 100 ms.
Protein identification and quantification
Database search and quantification were performed by
Proteome Discoverer v.1.4 software (Thermo Scientific).
The reference proteome set of Homo sapiens containing
canonic and isoform sequences was downloaded from
UniProt [21] (http://www.uniprot.org/) on Aug 18th 2014
and merged with the common contaminants file down-
loaded from the MaxQuant web page (http://www.cox-
docs.org/doku.php?id=maxquant:common:download_and
_installation); the merged database contained 89,252 se-
quences. The search parameters were as follows: digestion
with trypsin, max. 2 missed cleavages, allowed peptide
mass tolerance of 10 ppm, fragment mass tolerance of
0.02 Da, fixed carbamidomethylation of cysteine, vari-
able modifications: oxidation of methionine, acetyl-
ation of protein N-term and SILAC labels Arg10 a
Lys8. The strict target value of FDR for a decoy data-
base search of 0.01 was applied (high confidence).
Only unique peptides were considered for quantifica-
tion and the heavy to light ratios were normalized on
protein median for each replicate (Additional file 2:
Supplementary File 1).
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For relative protein quantification only protein groups
with a minimum of 2 identified peptides in all three repli-
cates and a minimum of 1 quantified peptide per each rep-
licate were considered. Log2 values of protein ratios from
each replicate were then subjected to the ranking test to
find the most significantly regulated proteins [22] taking
the protein groups found in top (T) or bottom (B) groups
in all three replicates (TTT or BBB). The false discovery
rate (FDR) was evaluated by non-parametric estimate as an
average number of proteins in the “false” groups (TTB,
TBT, BTT, BBT, BTB and TBB). The significance cut-off of
the FDR was set around 5 %. For analysis, only proteins
with a log2 fold change value of 1.2 or higher were consid-
ered (Additional file 3: Supplementary File 2). The mass
spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium [23] via the PRIDE partner
repository with the dataset identifier PXD001806.
Pathway and GO enrichment analysis
We performed an enrichment analysis of pathway-based
sets of proteins considering all the nodes of our
extended network. Enrichment was done employing
ConsensusPathDB, of the Max Planck Institute for
Molecular Genetics, by using the overrepresentation
analysis online tool. As input, we uploaded the UniProt
protein identifiers of all the elements of the extended
network. We searched against pathways as defined by
Reactome [24] and KEGG [25], with a minimal overlap
with the input list of 5 and a p-value cutoff of 0.001.
Also, employing the same website and the same analysis
tool, we performed an enrichment analysis based on Gene
Ontology (GO) [26] level 3 category of biological pro-
cesses. For this analysis, we considered only the identified
core proteins and set the p-value cutoff on 0.001.
Network construction
Network reconstruction was performed with the aid of the
Cytoscape Plugin, BisoGenet [27], using the identified pro-
teins as bait nodes and adding edges with the following
parameters: Organism >Homo sapiens, protein identifiers
only; Data Settings > protein-protein interactions; all data
sources and all experimental methods; method > By adding
edges connecting input nodes and as Output > Proteins.
The iRegulon plugin was used to predict their transcrip-
tional regulators using the default setting. Only predicted
transcriptional regulators with normalized enrichment
scores (NES) >3 were used.
Results
Gal-7 is downregulated in squamous cervical cancer,
high-grade squamous intraepithelial lesions and cervical
cancer cell lines
To get an insight into the galectin status of high-risk
human-papillomavirus (HPV)-induced tumors, we first
examined the expression of nine different members of
this gene family on microarrays from the Scotto cohort
[9] (Additional file 4: Figure S1). A significant down-
regulation of Gal-7 expression was observed in fresh
samples derived from squamous cell carcinoma (SCC),
as well as established HPV16/18-positive CaCx cell lines
(Fig. 1b). Considering the signal intensity of the microar-
rays, Gal-2 and Gal-3 transcription was also affected to
some extent in SCC/CaCx samples compared to normal
cervical tissue (Fig. 1b). However, in contrast to Gal-7,
these two galectins are not directly related to tumorigen-
esis [28]. Only Gal-7 negative regulation showed a high
statistical significance (Fig. 1b). This could be further
supported by the Zhai cohort [11] (Additional file 4:
Figure S1. B), where Gal-7 expression was also reduced
in high-grade squamous intraepithelial lesions (HSIL)
and in cervical cancer samples (Fig. 1c). Hence, the grad-
ual downregulation of Gal-7 in premalignant lesions and
a marked reduction in SCCs suggest that it might play a
role in the development of cervical cancer. We validated
our observations from the meta-analysis by qPCR and
Western blot (Fig. 1d). For this purpose, we also in-
cluded human keratinocytes that were separately immor-
talized by the E6-, E7- and E6/E7 oncoproteins of HPV
16 [29]. While CaSki, SiHa, and HeLa cells showed
almost a complete suppression of their mRNA steady-
state levels, Gal-7 was increased in immortalized cells
when compared with primary keratinocytes (Fig. 1d).
However, no significant differences among the same cells
could be discerned at the protein level (Fig. 1d, below).
Moreover, consistent with the microarray data (Fig. 1b),
clinical specimens obtained from SCC patients also
demonstrated a significant decrease (p < 0.05) of the
Gal-7 mRNA in biopsies when compared to normal con-
trol samples (Fig. 1e). Altogether, these data imply that
Gal-7 downregulation correlates with cervical cancer
progression.
Mutually exclusive expression of Gal-7 and Gal-1
determines clinical outcome and overall survival
In order to confirm the biological significance of the
negative regulation of Gal-7 in a clinical context, we an-
alyzed a cohort of patients to determine the correlation
between their survival rate and the absence or presence
of Gal-7 and Gal-1. Since Gal-1 is considered as a pro-
tumorigenic galectin [30], we anticipated a mutually ex-
clusive expression with respect to Gal-7 as an indication
of positive clinical outcome in cervical cancer. In order
to prove this assumption, we used Illumina 450 k data
from the Cervical Squamous Cell Carcinoma project of
The Cancer Genome Atlas (CESC-TCGA; n = 185) [31]
and performed an Unsupervised Hierarchical Clustering
analysis (UHC) (Fig. 2a). Here, two significantly dif-
ferentiated clusters (p = 0.0001) were obtained (Fig. 2b).
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Group A was integrated by 104 patients expressing high
levels of Gal-7 and low levels of Gal-1. In contrast,
group B revealed just the opposite composition (low
Gal-7 and high Gal-1 expression, data derived from 81
patients). Figure 2e shows a representative immunohis-
tochemical staining of Gal-1/Gal-7 in normal versus
tumor tissue (obtained from the Human Protein Atlas)
[32]. To address the clinical significance of the UHC ana-
lysis, we also assessed the overall survival in this cohort
through a Kaplan-Meier survival analysis. Intriguingly,
Group A had a significantly higher overall survival rate
when compared to group B (p < 0.0001) (Fig. 2c). These
results suggest that a mutually exclusive expression of
Gal-7 and Gal-1 has beneficial prognostic value in CESC
patients.
Tumors are known to downregulate incompatible
genes through epigenetic mechanisms, such as gene
methylation [33]. Therefore, we analyzed if this was the
mechanism behind Gal-7 repression in the cohort. We
found a high correlation (p = 0.001) between the clinical
Fig. 2 Analysis of Gal-1/-7 expression and survival in the TCGA-CESC cohort. a Hierarchical clustering of Gal-7 and Gal-1 expression in a 185-patient
panel of CESC from the TCGA. b Gal-7 and Gal-1 expression in TCGA-CESC patients. c Kaplan-Meier curve for 5000 days of overall survival in the CESC
panel of TCGA. Censored events were marked with vertical black lines. d Inverse correlation of Gal-7 expression and methylation. e Immunohistological
staining of Gal-1 and Gal-7 in normal and cervical cancer tissue sections (immunohistochemistry images were taken from the Human Protein Atlas
Project). Gal-1 was detected using the HPA000646 antibody. Gal-7 was detected using the HPA001549 antibody. (BMann Whitney test P < 0.0001
Gaussian Approximation two-tailed P-value; *** means highly significant. Clog-rank test; p= 0.005. DP< 0.0001, Spearman r, two tailed P value, alpha = 0.05)
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outcome and the degree of expression of the Gal-7 gene,
which in turn inversely correlated with methylation
(Fig. 2d) between positions −499 to +100 relative to the
initiation site (Additional file 1: Table S1). Our data
suggest that Gal-7 negative regulation is a biological
phenomenon with a strong impact in the outcome of
cervical cancer patients.
Hypermethylation is responsible for reduced Gal-7
expression in CaCx cells
As is indicated by the meta-analysis, we examined
whether the Gal-7 gene became de novo methylated dur-
ing the multi-step progression to cervical cancer. For
this purpose, cells were treated with 5′-azacytidine as a
demethylating agent. Re-expression of the Gal-7 gene
could be observed after demethylation (Fig. 3a). Protein
recovery was not as strong as in HPV16-immortalized
keratinocytes (Fig. 3a, right panel), implying that add-
itional mechanisms control endogenous Gal-7 expres-
sion or protein stability in CaCx cells [34].
In silico analysis using the Eukaryotic Promoter Database
[35] revealed several CpG sites at the 5′end as well as in-
side the gene (Fig. 3b). After bisulfite-sequencing, a methy-
lation pattern from positions −300 to −12 was almost
identical in all cell lines (Fig. 3b). Cervical carcinoma cells
revealed strong hypermethylation of CpG sites localized
within the first intron (at positions +2 to +132), whereas
the same region was almost methylation-free in HPV16
Gal-7+ immortalized keratinocytes. These data suggest a
gradual de novo methylation of Gal-7 during HPV-induced
carcinogenesis.
Reconstitution of Gal-7 in CaCx cells conferred sensitivity
to apoptosis and anchorage-independence
We next examined the phenotypic changes of CaCx cells
after retrovirus-mediated Gal-7 reconstitution in vitro
(Fig. 3c). Low-attachment and anchorage-independence
are well-known and stringent in vitro parameters for
transformation [17]. In a tumor formation assay in vitro,
colony formation capacity was found to be significantly
lower in Gal-7+ cells than in mock-transduced controls
(Fig. 3d). Moreover, re-expression also enhances the sus-
ceptibility to apoptotic stimuli, which is consistent with
the pro-apoptotic function of Gal-7 in keratinocytes
[36]. This was further confirmed by treating cells with
the specific Bcl-2 inhibitor and apoptosis inductor
HA14-1 [37]. Subsequent staining with the lipophilic
cationic dye JC-1 revealed lower cell viability as deter-
mined by the loss of the mitochondrial transmembrane
potential (ΔΨm) (Fig. 3e). Our data shows that Gal-7-
expressing cells are more susceptible not only to intrin-
sic, but also to extrinsic apoptotic signals [14]. We show
that the expression of Gal-7 decreases cell viability and
induces a apoptotic response in transfected cells.
Impact of Gal-7 re-expression on cellular networks of
CaCx cells
Having shown that Gal-7 re-expression negatively affects
cell growth and impairs colony formation by means of
apoptotic signals, we hypothesized that there are deep
changes in the cellular networks in response to Gal-7 re-
introduction. In order to analyze this question at system-
level, we combined the results from microarray expression
profiling (Fig. 4a) with a SILAC-based proteomic ap-
proach (Fig. 4b). In total, 213 candidate genes were identi-
fied in vitro as being differentially expressed either at the
RNA or protein level (38 in HeLa Gal-7+ and 185 in SiHa
Gal-7+ cells versus mock-transduced Gal-7- control cells).
Surprisingly, only three genes were differentially regulated
in HeLa Gal-7+ cells at the transcriptome level (Fig. 4c).
The proteomic analysis of HeLa/HeLa Gal-7+ revealed 35
proteins that were differentially expressed in three bio-
logical replicates (FDR 5 %, Fig. 4d). In the case of SiHa/
SiHa Gal-7+ cells, 60 mRNAs were found to be differen-
tially transcribed (Fig. 4e). The proteomic analysis showed
125 differentially regulated proteins (FDR 5 %, Fig. 4f).
The difference between transcriptome and proteome sug-
gests that there are post-transcriptional regulation mecha-
nisms affecting protein expression levels.
To study the biological processes in which the identified
molecules are involved, we performed a functional analysis
of proteins and transcripts using levels 3 and 4 of the
“Biological processes” Gene Ontology (GO) [38] through
which 120 GOs were obtained (q-value = 0.001). We con-
densed the redundant GOs to obtain “functional modules”
by pooling the GO domains according to their participa-
tion in pathways and cancer hallmarks [39]. As summa-
rized in Fig. 4g and h (Additional file 1: Table S4 and S7),
HeLa/HeLa Gal-7+ and SiHa/SiHa Gal-7+ shared eight
functional modules, but their composition and the extent
of regulation between them was different. Moreover, two
additional modules were recognized in SiHa, namely
“Signal transduction” and “Post-translational modifica-
tions” (Fig. 4h). Notably, although we studied the same
cancer entity, our proteo-transcriptomic data show that
re-expression of Gal-7 can trigger different cell-context
dependent responses but leads to a convergent phenotype,
as reflected in specific biological processes and cancer
hallmarks.
Mouse microenvironment pressure exerts differential
gene expression in Gal-7+ tumors
To investigate if Gal-7 reconstitution impairs the tumori-
genicity of xenografts, HeLa and SiHa Gal-7 + cells, as
well as their mock Gal-7- control cells, were subcutane-
ously injected into athymic nude mice and tumor growth
was monitored. The tumors were excised when they
reached a volume between 800–1000 mm3 and were used
for transcriptome analysis (Fig. 5a). Consistent with the
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Fig. 3 Methylation analysis and re-expression of Gal-7 in CaCx cell lines. a qPCR and Western blot of Gal-7 four days after 5′-Azacyditine (Aza)
treatment. Actin was used as the loading and transfer control. b Above: schematic overview of the Gal-7 gene: the locations of CpG sites, the
transcriptional start site (TSS) and the first exon are indicated. Below: percentage of methylation after bisulfite pyrosequencing analysis. c Western
blot after reconstitution of Gal-7 in CaCx cells and mock infected control cells. Tubulin was used as the loading and transfer control. d Colony
formation assay of Gal-7+ CaCx cells (Gal-7+, red) versus mock-infected cells (Gal-7-, black). e Induction of apoptosis due to loss of the mitochondrial
transmembrane potential after incubating Gal-7+ and Gal-7- CaCx cells with increasing amounts of H14-1. (CKruskall-Wallis P < 0.0001, Dunn’s Multiple
Comparison Test P < 0.05; E, F G T Test, P < 0.05, ** means moderated significant)
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Fig. 4 Changes in gene and protein expression in Gal-7+ CaCx cell lines. a Experimental strategy for differential gene expression analysis in
Gal-7+ CaCx cell lines. b SILAC proteome experiments for the profiling of Gal-7+ cell lines. c-f Differentially expressed transcripts in HeLa (c) and
SiHa (e) Gal-7+ cell lines in vitro with respect to Gal-7- controls. The X axis is the P value in log10 scale; the Y axis is the fold change. Differentially
expressed proteins between HeLa (d) and SiHa (f) Gal-7+ cell lines in vitro are shown aside. The X axis represents the score in log10 scale (the
identification score was obtained from the average score reported by triplicate identification experiments) and the Y axis is the fold change (FC).
g, h Functional modules affected in Gal-7+ HeLa (g) and SiHa (h) cells (red: up-regulation, blue: down-regulation)
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lower colony formation capacity and higher sensitivity to
apoptotic signals under in vitro conditions, both HeLa
Gal-7+ (Fig. 5b, d) and SiHa Gal-7+ cells (Fig. 5c, e) showed
a significant impairment in their tumor formation capacity.
To understand this phenomenon at the molecular level,
we performed microarray gene profiling to monitor
changes that could be linked to decreased tumorigenicity
and animal survival. A total of 42 differentially expressed
genes were found in HeLa Gal-7+ cells (Fig. 5f) that could
be divided in 8 functional modules (Fig. 5h, Additional
file 1: Table S4). In SiHa Gal-7+ cells, 58 genes were differ-
entially regulated (Fig. 5g), and these could be split into 10
functional modules (Fig. 5i, Additional file 1: Table S7),
where only PLAC8 and TCN1 were in common. On the
other hand, Gal-7 re-expression led to the identification of






Fig. 5 The microenvironment induces changes in Gal-7+ tumors. a Experimental strategy. b and c Growth of Gal-7+ and Gal-7- Hela and SiHa
tumors. d and e Incidence of tumors in injected mice. f, g Gene profiling analyses in Gal-7+ and Gal-7- HeLa and SiHa tumors. X axis: P value in
log10 scale, Y axis: fold change (FC). h, i Functional modules and differentially expressed transcripts in Gal-7+ HeLa. h and SiHa (i) tumors in vivo.
(B C D E ***p < 0.001; **p < 0.01; *p < 0.05 Student’s t test). (red: up-regulation, blue: down-regulation)
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at transcriptional or translational level (OASL, COX19,
FAM129A/NIBAN, CDKN2A/p14arf, CRYAB, BCL3, FST
and TACSTD2) (Fig. 6b). We validated their expression by
qPCR, and observed whether the same genes were af-
fected when Gal-7 reconstituted HPV16-positive CaSki
cells were examined (Additional file 5: Figure S2). Our
data indicate that Gal-7 has a general impact on these
network components, which are shared among the three
different cervical carcinoma cell lines. These results high-
light the complex influence of the microenvironment on
the modulation of gene expression in comparison to the
in vitro growth.
Living systems are dynamic and complex. Their
behavior may be hard to predict from the properties of
individual parts, since their interactions produce emer-
gent properties [40, 41]. To get a more accurate insight
into the emergent properties of the Gal-7-dependent
regulation, we performed an integrative analysis using
the transcriptome and proteome biological layers
(Fig. 6a). We used the Cytoscape software [42] to build a
network for each cell line, and we made a prediction of
transcriptional factors (TFs) with iRegulon [43]. The en-
tities were grouped according to their participation in
each synthetic module. In HeLa Gal-7+ cells (Fig. 6c),
five major TFs are able to control about 60 % of all the
genes in the network; these are SP9, ARID3A, MYF5,
IKZF2 and SCRT2 (Additional file 1: Table S5). When
the function of each individual module was dissected, we
found an up-regulation of several candidates involved in
the impairment of growth and proliferation (cell cycle
and proliferation/regulation of programmed cell death
modules), but also in cell adhesion, migration, metabol-
ism, tissue organization and integrity.
The integrative analysis of SiHa Gal-7+ cells (Fig. 6d)
showed 6 major TFs that are able to regulate up to 65 %
of the genes within this network: E2F1, E2F6, EP300,
A D
C D
Fig. 6 Differential network analysis of Gal-7+ CaCx cells and tumors. a Integrative analysis strategy. b Common candidates that were differentially regulated
at the transcriptional or translational level compared against their Gal-7- controls. Numbers indicate fold changes. c, d Differential network analysis in
Gal-7+ HeLa and SiHa cells and tumors. Color depth represents the fold change with respect to the control. Red: up-regulation, blue: down-regulation.
Major transcription factors (MTF) are shown in the center. The colored lines derived from MTFs show the transcriptional relationship. The shape of the
symbols indicates the following: square for transcript, circle for protein, hexagon for TF, diamond for miRNA, and triangle for lncRNA. Wide, green shape
edges represent that the information for this molecule was obtained in vitro, while the thin, black edges mean in vivo molecule information
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SMAD1, NFIC and FOXJ3 (Additional file 1: Table S6).
Despite having different members, we found a regulation
of the same modules that were present in HeLa Gal-7.
This could account for the similar phenotypes showed
by our xenotransplantation analysis. Notably, there were
also changes in genes involved in post-translational
modifications and signaling transduction, two modules
that were not identified in the Hela Gal-7 network
(Additional file 1: Table S7).
Gal-7 re-expression in tumors modulates transcriptional
changes in their associated microenvironment
Xenografting of human cancer cells into mice gives us a
unique opportunity to study the crosstalk between the
tumors and their microenvironment. To follow that
purpose, we analyzed how Gal-7 reconstitution shapes
the behavior of the microenvironment and the infiltra-
tion of immune cells into tumor tissues. To selectively
obtain the gene expression profile of infiltrates (e.g.
tumor-associated-epithelial, stromal, vascular and im-
mune cells), we followed the competitive cross-species
hybridization of microarray experiment (CHME) strategy
[44] of the xenografts (Fig. 7a). In the HeLa-Gal-7+
Tumor associated microenvironment (TAM), a total of 87
differentially regulated mouse genes were revealed
(Fig. 7b). Subsequent functional module analysis assem-
bled these genes into 9 modules (Fig. 7d), where “tissue
morphogenesis”, “metabolism and transport”, and “che-
mokine activity and immune response” comprised most of






Fig. 7 Differential gene profiling of the Gal-7+ tumor associated microenvironment. a Experimental strategy. b, c Differential gene profiles of the
of Gal-7+ HeLa and SiHa TAM with respect to controls. X axis: P value in log10 scale; Y axis: fold change (FC). d, e Modules and differentially
expressed transcripts in Gal-7+ HeLa (d) and SiHa (e) TAM (up-regulation in red, down-regulation in blue)
Higareda-Almaraz et al. BMC Cancer  (2016) 16:680 Page 14 of 22
“hypoxia response” appears only in this TAM. In the SiHa
Gal-7+ TAM, 91 differentially regulated genes were found
(Fig. 7c). 11 functional modules could be clustered
(Fig. 7e), mostly showing a strong down-regulation in
their differentially expressed genes. Notably, while in the
HeLa-Gal-7+ TAM the genes related to “chemokine activ-
ity and immune response” and “proteases” were over-
regulated, in the corresponding modules of the SiHa-Gal-
7+ TAM all the genes were down-regulated. Also remark-
able is the inclusion of two additional modules in the
SiHa-Gal-7+ microenvironment: “calcium signaling” and
“degradation of macromolecules”. These results suggest
that the mechanisms that determine the growth impair-
ment phenotype in response to Gal-7 reconstitution de-
pend on the cellular context, supporting the notion of the
uniqueness of cancer cells.
We made a network and TF analysis of the TAM’s of
the Gal-7+ tumors. In the HeLa-Gal7+ TAM, regulation
of all 9 modules could be attributed mainly to three
mouse TFs: Arfgap1, Egr1 and Srf (Fig. 8a and Additional
file 1: Table S8). Interestingly, in the “Regulation of
transcription” module we found the down-regulation of
the Abra gene, which activates Srf and Egr1 [45, 46]. This
confirmed our TF prediction and could provide an ex-
planation for the generalized down-regulation of genes. In
the “chemokine activity and immune response” module,
an up-regulation of several genes (Additional file 1: Table
S9) could be discerned, arguing for a wide immune host
response against the Gal-7 expressing tumor.
To further support the potential immune mechanism
in this system, differentially expressed genes were also
analyzed using the immunological genome project (IGP)
database [47]. The HeLa Gal-7+ mouse microenviron-
ment was enriched with the expression of Stfa1, Stfa2,
Retnlg, S100a8 and S100a9. The two latter marker genes
are constitutively expressed by neutrophils, activated
monocytes and macrophages. We also identified IL1β,
CXCL2, CCL3, CCL4 and Arg1, characteristic genes
expressed in macrophages, NK cells, and activated
polymorph-nuclear neutrophils, respectively. Moreover,
Galnt9 is present only in macrophages and monocytes
(Additional file 6: Figure S3B), while Zmynd19 expres-
sion is found within hematopoietic stem and multi-
lineage progenitor cells (Additional file 6: Figure S3A).
The SiHa Gal-7+ microenvironment network analysis
showed strong repression in all the functional modules.
The major TFs that drove the network were Trp53,
Nr2c2 and Mecom (Fig. 8b and Additional file 1: Table
S10). A detailed description of some important genes is
provided in Additional file 1: Table S11.
Using the IGP database, we mapped the up-regulated
genes in the SiHa Gal-7+ mouse microenvironment. Here,
we found that the expression of Taf15 (TATA Box Binding
Protein (TBP)-Associated Factor), amongst others, was
A B
Fig. 8 Differential network analysis of the Gal-7+ tumor associated microenvironment. Differential network analysis in Gal-7+ HeLa (a) and SiHa
(b) TAM. Color depth represents the fold change. MTFs are shown in the center. The colored lines derived from MTFs show the transcriptional
relationship. The shape of the symbols indicates the following: square for transcript, hexagon for TF, and triangle for lncRNA (up-regulation in red,
down-regulation in blue)
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restricted to B-cells, dendritic and NK cells, but not to
stromal cells. Whether SiHa Gal-7+ cells induce an
environment that suppresses the infiltration of tumor-
associated stromal and immune cells awaits further eluci-
dation. Altogether, these data suggest a possible role of
the innate cytotoxicity and an adaptive antibody and cyto-
kine secretion mechanism in the growth impairment of
SiHa Gal-7+ tumors.
Discussion
Cervical cancer is a highly robust and flexible network
[48] that is shaped by particular microenvironments
[49]. Consequently, the combination of clinical data and
integrative system-level approaches [50–53] is necessary
to tackle the inherent complexity of the disease [54, 55].
In fact, the network of CaCx cells is deeply influenced
by the expression of the E6 and E7 high-risk-HPV onco-
proteins, which always attack hubs to get selective
advantage [56, 57]. These events occur not only via inter-
fering with the p53 and the retinoblastoma (pRB) pathways
[58], but also through a direct evasion of anti-tumorigenic
responses by 1) impairing central immunomodulatory mol-
ecules including type I interferons [59], IL-1β [60], and
chemokines [61], and 2) acquiring resistance to immune
(CTL and NK)-mediated apoptosis [62, 63].
Gal-7 is incompatible with the malignant phenotype in
cervical cancer
Gal-7 possesses well known functions in pro-apoptotic
response [7, 64, 65], regulation of cellular proliferation
[66], and epithelial homeostasis [67]. In our study, sev-
eral lines of evidence pinpointed Gal-7 as incompatible
with the selection process during cervical carcinogenesis.
Such phenomenon is clearly visible in the negative regu-
lation of the gene at the transcript and protein level, in
clinical samples as well as in cell lines. As shown by
bisulfite sequencing in our cell lines and meta-analysis
of methylation arrays from clinical samples, the absence
of Gal-7 could be attributed to an intragenic de novo
methylation event, a mode of gene silencing also ob-
served in gastric cancer [68]. Gal-7 expression, however,
could be restored by treating cell lines with a demethy-
lating agent (Fig. 3a).
As depicted in our results, Gal-7 reconstitution does
not lead to the suppression of the tumorigenesis, but
rather results in a significant reduction of colony forma-
tion capacity and an increased sensitivity towards apop-
tosis in vitro, consistent with observations in prostate
cancer cells [65] and in colon carcinoma cells [69].
Xenotransplantation in nu/nu mice also showed a strong
tumor growth retardation, a phenotype in common with
Gal-7+ colon carcinoma cells in SCID mice [69]. Inter-
estingly, other cancer models display an opposite behav-
ior. Gal-7 is over-expressed in lymphoma cells and is
related to promoting tumorigenesis by induction of
MMP9 [70] and in ovarian cancer it is associated with
cell proliferation and poor prognosis [71].
Gal-7 reconstitution triggers changes in proteins and
mRNA in the cell lines and tumor
Our results demonstrated that re-expression of Gal-7 in
the HeLa and SiHa cell lines triggers a cascade of changes
at both transcript and protein levels. In vitro, HeLa Gal-7+
only yielded 3 differentially expressed genes and 35 pro-
teins, while in SiHa Gal-7+ we found 60 differentially
expressed transcripts and 125 proteins. Several studies
show significant differences between the abundance ratio
of the messenger RNA transcript and the corresponding
protein product [72, 73], a phenomenon that could be
mainly due to post-transcriptional and translational regula-
tion, as well as protein and mRNA turnover [74].
Within tumors, a continuous selection exists for cells
with the highest survival and proliferative advantage;
moreover, microenvironmental conditions provide select-
ive pressure for tumor evolution and the progression to
invasion [75]. One of the most probable mechanisms for
inhibition of the tumor growth could be the expression of
genes with “asymmetric activity” capable of suppressing
tumorigenicity, without affecting in vitro growth [76].
Three central points can be extracted from the present
work, the first of which is related to the robustness of
the cancer network. Despite the gene composition, there
is a powerful convergence in the functional modules
towards the hallmarks of cancer, as suggested by our
previous work [48]. A factor to be discussed is if these
functional modules are a response to the imminent cell
destruction, a desperate response to survive, or a com-
bination of both. An example in HeLa Gal-7+ cells is
the case of over-expression in vitro (protein) and in vivo
(transcript) of SERPIN3B, a protease inhibitor that might
act in protecting cancer cells through inhibition of
apoptotic signals [77, 78] and is capable of inducing
epithelial-mesenchymal transition [79]. Another one is
the over-expression of GAGE genes in SiHa Gal-7+ cells,
whereas their expression in normal tissues is limited to
the germ cells of immune-privileged organs [80]. It is
possible to speculate whether this response is an attempt
to escape the immune modulation.
System-level response in Gal-7 network is context
dependent
We selected the SiHa and HeLa cell lines because they are
transformed by the most frequent high-risk HPV types
(HPV16 and HPV 18, respectively). The E6/E7 oncopro-
teins of both HPV types possess subtle differences in their
interaction partners [81], in the affinity of these interac-
tions [82] and, consequently, in the mechanisms of trans-
formation [83, 84]. These differences could potentially
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generate a chain reaction in the whole cell network, and
each cell line could give a particular response due to its
specific background. Although tumors of similar types
and clinical outcomes can have patterns of gene expres-
sion or mutations that are strikingly different, these behav-
iors recurrently target the same pathway or network [55].
Which leads us to central point number two: while each
cancer is as unique as its patient, there is convergence to-
wards a very similar phenotype.
Although Gal-7 affects the specific cervical cancer net-
works in different ways, we identified a group of eight
molecules that are regulated in both cell lines: CRYAB,
TACSTD2, BCL-3, COX19, OASL, CDKN2A/p14ARF,
NIBAN/FAM129A, and FST. All these proteins have
been previously described as key regulators of tumori-
genesis in some cancers (Table 1).
In our differential network analysis, we predict the TFs
that can potentially regulate the respective modules. The
HeLa Gal-7+ network can be controlled by five major
TFs: SP9, ARID3A, MYF5, IKZF2 and SCRT2, while in
SiHa Gal-7+ cells, six major TFs could be identified:
E2F1, E2F6, EP300, SMAD1, NFIC and FOXJ3 (Add-
itional file 1: Tables S5 and S6). Surprisingly, we found a
deep connection involving E2F TFs in both cell lines. In
HeLa-Gal-7+, ARID3A, also known as E2FBP1, is a TF
involved in the control of cell cycle progression by the
RB1/E2F1 pathway, and is induced in response to p53
[85, 86]. In the SiHa-Gal-7+ network, E2F1, E2F6, and
FOXJ3 are involved in pathways of cell cycle control,
where FOXJ3 may be involved in regulating a network
of zinc finger–binding proteins that may affect gene ex-
pression themselves in response to the E2F pathway [87,
88]. E2F TFs are part of a wide network involved in dif-
ferentiation, apoptosis and immune response [89–91].
Gal-7 plays a role in the crosstalk between cancer cells
and the tumor associated microenvironment
Since a tumor is always composed of heterogeneous cells
in a context-dependent manner [92], expression profiling
of infiltrates provides an insight into the bi-directional
communication between transformed cells and the
microenvironment. Our CHME strategy allowed us to
monitor the expression profile of genes that were indica-
tive of the infiltration of potential tumor-associated epi-
thelial, stromal and immune cells [93, 94].
The integrative analysis of Gal-7+ TAM cells revealed
deep changes, presumably activated by the interaction of
the tumor and microenvironment networks. In the HeLa
Gal-7+ TAM, the chemokine and immune responses
stood heavily stimulated. Meanwhile, 30 genes related to
tissue morphogenesis, metabolism and transport, and
hypoxia response were down-regulated. Excitingly, we
found the interplay between Abra (STARS) and its
targets, Srf and Egr1. These three TFs have an important
role in the remodeling, homeostasis and metabolism of
skeletal muscle [95], and appear to be under control of
AKT [96]. In the SiHa Gal-7+ TAM, there is not an ob-
vious interplay between the predicted and regulated TFs.
Nevertheless, we observed the negative regulation of
almost 97 % of all the modules, and specifically of some
genes that promote carcinogenesis, such as CCL5,
CXCL9 and CXCL10 (see Additional file 1: Table S11).
These genes are characteristic of tumor-associated mac-
rophages and stromal fibroblasts.
It is noteworthy that the role of the immune system is
highlighted by the expression of specific genes of NK
cells in the HeLa Gal-7+ TAM. Meanwhile, in SiHa Gal-
7+ TAM, we found evidences of activated monocytes
and the infiltration of macrophages. This would indicate
that the innate and adaptive immune system, stroma
cells, and fibroblasts play a complex leading role in
impairing the growth of Gal-7+ tumors.
These observations sustain the third central point of our
work: there is an aggressive negotiation between the tumor
and the TAM, where constant changes in both networks
shape their overall behavior and fate. We summarize our
three central points in Fig. 9. Supporting our empirical ob-
servations, formal mathematical modeling demonstrated
Table 1 Common proteins between Hela and SiHa Gal-7+ cell networks
Name Process Model Reference
CRYAB Associated with poor prognosis and metastasis, negative regulator of TRAIL-mediated
apoptosis, related to hypoxic survival and metastasis
Several [101–103]
TACSTD2 Correlated with malignant progression, apoptosis resistance and proliferation Cervical [104–106]
BCL-3 Negative regulator of apoptosis Several [107, 108]
COX19 Biogenesis and regulation of mitochondrial respiratory homeostasis Several [109, 110]
OASL Displays antiviral activity, responsive to type I interferon signal Several [111, 112]
CDKN2A Overexpression is used as a biomarker for progressing lesions Cervical [113]
NIBAN/FAM129A Anti-apoptotic activity Several [114–116]
FST Attenuates rRNA synthesis and trigger FST-mediated apoptosis Cervical, Breast [117, 118]
Common regulated proteins in the HeLa and Siha Gal-7+ cell networks and their associated functions in different cancer models
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that tumor mass evolution is the integrated result of the
dynamics of two linked complex systems, tumor cell popu-
lation and tumor microenvironment [97], in addition to
emergent properties caused by the genomic background
[98] and clinically significant macro-environmental vari-
ables [99, 100].
Numerous studies reinforce the hypothesis of a complex
control by the stem cells over their niche, allowing for im-
munologic privilege. This effect allows them to exert their
multipotentiality and proliferate at a different rate than the
rest of the tissue [85–87]. Excitingly, it is known that se-
creted galectins are able to exert immunomodulation in the
stem cell niche [88]. For instance, Gal-9 has recently been
shown to prevent allo-reactivity of immune cells in a non-
cancerous model [89], and has been shown to be a major
mediator of the anti-proliferative and functional effects of
multipotent mesenchymal stromal cells on T and B cells
[90]. Moreover, Gal-3 is over-secreted in pancreatic cancer
stem-like cells [91]. The interaction with stem cells could
explain why Gal-1 and Gal-3 were found to drive a strong
immunomodulation in cancer in a previous work [1].
Based on the previous evidence, we speculate that
galectins (including Gal-1 and Gal-7) could act like mo-
lecular masterminds behind the regulation of immune
activity in different cancers, particularly through interac-
tions with stem cells. A delicate equilibrium in galectin
expression could regulate immunosurveillance, while its
disturbance by tumors and cancer stem cells would lead
to immune escape, tumor growth and metastasis. In our
Gal-7+ xenografts, the re-expression of Gal-7 could have
either restored immunosurveillance or counteracted any
immune escape mechanisms, which would explain the im-
mune signature found in the TAM. Future studies should
confirm if Gal-7 plays a direct role in the recruitment of
immune cells, as well as whether they interact in any way
with cancer stem cells to achieve such results.
Conclusions
Gal-7 expression presents an interesting correlation with
a significantly better survival rate of patients diagnosed
with cervical cancer. This phenomenon highlights the
biological importance of Gal-7 repression in CaCx.
Fig. 9 Bidirectional crosstalk between Gal-7+ tumors and their associated microenvironments. The expression of genes related to stromal cells,
cancer associated fibroblasts, and immune cells results in an aggressive crosstalk that could potentially decide the fate of the tumor: proliferation
and immune evasion, or immune destruction. The role of the common proteins in the Gal-7 network remains partially unknown. The color of the
participant transcripts and proteins represents differential expression (up-regulation in red, down-regulation in blue)
Higareda-Almaraz et al. BMC Cancer  (2016) 16:680 Page 18 of 22
The cellular networks reconstructed by Gal-7 expres-
sion prove three central hypotheses implicated in the
emergency of properties of the Gal-7 network: 1) Despite
the gene composition, there is a convergence in functional
modules that potentially govern the retardation of growth
in CaCx Gal-7+ cells. 2) Regardless of their anatomical
and cellular origin, each cancer is as unique as its patient.
3) A tumor-microenvironment cross-talk in response to
Gal-7 reconstitution leads to an alteration of regulation
and interaction networks, providing a great insight into
molecular basis of the Gal-7 network.
Integrating several biological layers of information and
comparing the variability of the dynamics and the com-
plexity of the networks, using tools of the emergent field
of differential network biology, is essential to gain defini-
tive insights into cancer biology at the molecular level.
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